Interim Report January – June 2021

Financial reports 2021 2021   2020   2019   2018   2017   2016   2015   2014   2013 Interim Report January – June 2021>> About CombiGene CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life...

read more

Interim Report January – March 2021

Financial reports 2021 2021   2020   2019   2018   2017   2016   2015   2014   2013 Interim Report January – March 2021 >> About CombiGene CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life...

read more

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.

 

 

CombiGene AB, Medicon Village, SE-223-81 Lund

 

Linked In     Twitter      Facebook